Article
Oncology
Kai Yang, Ya-Lin Wang, Zhen Zhu, Xin-Hui Cao, Ming-Xing Liang, Di Xu, Yin-Jiao Fei, Si-Yuan Yang, Hong-Lei Zhou, Jin-Hai Tang
Summary: Breast cancer is a major cause of cancer death worldwide. Targeted drugs have improved the survival rate of breast cancer patients, but some patients still do not respond to current treatments. Identifying new therapeutic targets for breast cancer is important. This study identified core heterochromatin-related genes in breast cancer using prognostic survival analysis. The expression of CBX3, a heterochromatin-related protein, was found to be higher in breast cancer compared to normal tissue. Knockdown of CBX3 inhibited breast cancer cell growth, migration, and invasion, while overexpression of CBX3 promoted these processes. CBX3 might promote breast cancer by modulating the ERK1/2 signaling pathway and EMT-related genes. CBX3 could serve as a biomarker and a potential therapeutic target for breast cancer.
Article
Cell Biology
Xiaodong Xu, Ke Zong, Xinxing Wang, Dongwei Dou, Pengwei Lv, Zhe Zhang, Hongwen Li
Summary: Aberrant expression of miR-30d in pancreatic cancer is associated with poor prognosis and early relapse of patients. The tumor suppressive effect of miR-30d is mediated through direct targeting of SOX4, leading to inhibition of the PI3K-AKT signaling pathway and repression of pancreatic cancer cell growth and metastasis.
CELL DEATH & DISEASE
(2021)
Article
Medicine, Research & Experimental
Yunxia Liu, Xia Liu, Yanhua Zhou, Tingting Liu, Jie Li
Summary: The study revealed that high expression of miR-27a in cholangiocarcinoma patients is associated with lymph node metastasis, TNM stages, and poorer overall survival. Overexpression of miR-27a promotes cell proliferation, migration, and invasion in CCA, while knockdown suppresses these processes. These findings suggest the potential utility of miR-27a in prognosis and progression of CCA.
CLINICAL AND EXPERIMENTAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Gabriele Feigelman, Elina Simanovich, Phillipp Brockmeyer, Michal A. Rahat
Summary: Metastasis is responsible for most colorectal cancer deaths. Cancer cells undergo epithelial-to-mesenchymal transition (EMT) to promote migration. CD147/EMMPRIN controls entry and exit from dormancy in CT26 colon carcinoma cells. Knocking down EMMPRIN expression pushes cells towards dormancy, while co-culture with macrophages can promote an exit from dormancy. The study suggests that EMMPRIN acts as a gatekeeper for dormancy and macrophages play a role in promoting tumor growth.
Article
Cell Biology
Xiaosheng Wu, Hao Wang, Danping Zhu, Yixia Chai, Jing Wang, Weiyu Dai, Yizhi Xiao, Weimei Tang, Jiaying Li, Linjie Hong, Miaomiao Pei, Jieming Zhang, Zhizhao Lin, Jide Wang, Aimin Li, Side Liu
Summary: This study reveals the mechanism of how deubiquitinating enzyme USP3 promotes tumor progression and metastasis in gastric cancer. The downstream targets of USP3, COL9A3 and COL6A5, are identified using isobaric tags technique. The results show that USP3 interacts with and stabilizes COL9A3 and COL6A5 through deubiquitination, playing a crucial role in the oncogenic activity of USP3 both in vitro and in vivo.
CELL DEATH & DISEASE
(2022)
Article
Obstetrics & Gynecology
Yu-feng Gong, Yu Zhang, Li-yang Li, Wen Han, Yang Liu
Summary: miR-599 is downregulated in cervical cancer and is associated with lymph node metastasis and FIGO stage. Overexpression of miR-599 suppresses cell proliferation, migration, and invasion in cervical cancer cells, indicating its tumor suppressor role.
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY
(2022)
Article
Cell Biology
Zhan Yang, Ya-Xuan Wang, Jin-Kun Wen, Hai-Tao Gao, Zhen-Wei Han, Jin-Chun Qi, Jun-Fei Gu, Chen-Ming Zhao, Hong Zhang, Bei Shi, Dan-Dan Wang, Xiao-Lu Wang, Chang-Bao Qu
Summary: SF3B4 is overexpressed in clear cell renal cell carcinoma (ccRCC) and negatively correlates with overall survival of patients. Upregulation of SF3B4 promotes ccRCC cell migration and invasion through the Twist1-mediated EMT process. Additionally, SF3B4 facilitates KLF16 expression, leading to transcriptional activation of Twist1 and further progression of ccRCC. These findings suggest that targeting the SF3B4-KLF16-Twist1 axis may be a novel therapeutic approach for ccRCC treatment.
CELL DEATH & DISEASE
(2023)
Article
Cell Biology
Wei Lv, Yan Li, Liye Fu, Fandong Meng, Jun Li
Summary: This study found that the expression levels of linc01133 were significantly increased in RCC tissues, and overexpression of linc01133 promoted cell proliferation, migration, and invasion while interference of linc01133 inhibited these processes.
Article
Multidisciplinary Sciences
Xiaoyu Niu, Keyuan Zhao, Yuanyuan Zheng, Yapeng Wang, Ruoyang Liu, Yiming Zhang, Lihui Wang, Yongjun Wu, Xuefeng Bai, Baoping Qiao
Summary: Emerging evidences indicate that ANXA13 is upregulated in ccRCC and promotes cell proliferation, migration, invasion, and apoptosis. Thus, ANXA13 may serve as a potential biomarker and therapeutic target in ccRCC.
Article
Cell Biology
Shaowei Mao, Di Zhang, Luan Chen, Jie Tan, Yunpeng Chu, Sijia Huang, Wenqi Zhou, Hengwei Qin, Qinghua Xia, Yueran Zhao, Rongxiu Li, Shengying Qin, Muyun Wei
Summary: Metastasis is a serious risk for RCC patients and understanding the molecular mechanisms underlying it is crucial for developing new therapeutic approaches. Studies have shown that FKBP51 may play a role in regulating ECM function and promoting invasion and migration of tumor cells in RCC. The study found that FKBP51 promotes ccRCC invasion and migration by binding with TIMP3, connecting it with Beclin1 complex and increasing autophagic degradation of TIMP3.
CELL DEATH & DISEASE
(2021)
Article
Biotechnology & Applied Microbiology
Rui Xin, Danhua Qu, Huiying Xu, Dawei Chen
Summary: The study reveals the crucial roles of circ_001504 and miR-149 in the progression of renal cell carcinoma, showing that circ_001504 acts as a competing endogenous RNA to enhance NUCB2 expression by sponging miR-149, ultimately affecting the progression of RCC.
CANCER GENE THERAPY
(2021)
Article
Cell Biology
Yi Zhang, Jie Li, Huayang Chen, Changmao Zhang, Song You, Yue Zhao, Xiaoning Lin, Yaqi Yu, Fei Fang, Ting Fang, Xiaomin Wang
Summary: RNF5 expression is significantly increased in HCC tissues and associated with larger tumor size, more satellite foci, and higher AFP levels. RNF5 promotes proliferation, migration, and invasion of HCC cells in vitro and facilitates HCC growth in vivo, suggesting it as a potential prognostic biomarker and therapeutic target for HCC patients.
Article
Oncology
Wenting Zhong, Hongxia Liu, Feng Li, Youyu Lin, Yan Ye, Luyun Xu, ShengZhao Li, Hui Chen, Chengcheng Li, Yuxuan Lin, Wei Zhuang, Yao Lin, Qingshui Wang
Summary: This study revealed overexpression of LIF in ccRCC and its association with poor prognosis. A predictive model for prognosis was established based on LIF-related genes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Shuangjie Liu, Lei Dou, Miao Miao, Xiaojun Man, Baojun Wei, Zhaowei Jiang, Yongze Ouyang, Toshinori Ozaki, Meng Yu, Yuyan Zhu
Summary: miR-138-2 functions as a novel epigenetic regulator of pro-oncogenic NOTCH1 pathway in renal cell carcinoma (RCC). It directly targets APH1A, MAML1, and NOTCH1 for the synergistic inhibition of NOTCH1 signaling. The feedback regulatory loop composed of HES1, miR-138-2, and NOTCH1 contributes to the malignant development of RCC.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Cell Biology
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang
Summary: CFI is overexpressed in glioma and is associated with poor outcomes, serving as a potential prognostic biomarker and driving malignant progression in glioma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Urology & Nephrology
Gaku Yamamichi, Taigo Kato, Satoru Yumiba, Eisuke Tomiyama, Yoko Koh, Kosuke Nakano, Makoto Matsushita, Yujiro Hayashi, Yu Ishizuya, Tadashi Watabe, Koji Hatano, Atsunari Kawashima, Takeshi Ujike, Yutaka Ono, Tsuyoshi Takada, Shingo Takada, Ryoichi Imamura, Norio Nonomura, Motohide Uemura
Summary: This study found that tartrate-resistant acid phosphatase type 5b combined with PSA is an independent biomarker for detecting bone metastasis in prostate cancer patients, and established a predictive model based on these two markers, which can effectively predict the clinical outcomes of patients.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Oncology
Saizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, Mamoru Hamaguchi, Ken Kuwahara, Mamoru Hashimoto, Shogo Adomi, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Hirotsugu Uemura
Summary: Switching from enzalutamide or apalutamide to darolutamide may be an effective therapeutic option for patients with non-metastatic castration-resistant prostate cancer. This retrospective study demonstrated that approximately 55.5% of patients had a PSA decline >50% after switching to darolutamide, with an average PSA decline of 73%.
Article
Oncology
Mamoru Hashimoto, Kazutoshi Fujita, Eisuke Tomiyama, Saizo Fujimoto, Shogo Adomi, Eri Banno, Takafumi Minami, Tetsuya Takao, Masahiro Nozawa, Hiroaki Fushimi, Kazuhiro Yoshimura, Norio Nonomura, Hirotsugu Uemura
Summary: This study investigated the relationship between nectin-4 and HER2 and EGFR in patients with upper urinary tract urothelial carcinoma (UTUC). The results showed high expression of HER2, EGFR, and nectin-4 in UTUC patients. Combination targeted therapy for HER2, EGFR, and nectin-4 may be an effective treatment option for UTUC patients.
ANTICANCER RESEARCH
(2023)
Article
Oncology
Toshiki Oka, Koji Hatano, Yohei Okuda, Akinaru Yamamoto, Toshihiro Uemura, Gaku Yamamichi, Eisuke Tomiyama, Yu Ishizuya, Yoshiyuki Yamamoto, Taigo Kato, Atsunari Kawashima, Kazutoshi Fujita, Norio Nonomura
Summary: This study analyzed patients with castration-resistant prostate cancer (CRPC) who received enzalutamide as first-line therapy. The results showed that lymph node metastasis and time to CRPC can predict the PSA response rate and PSA-progression-free survival of patients treated with enzalutamide.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Satoshi Katayama, Benjamin Pradere, Nico C. Grossman, Aaron M. Potretzke, Stephen A. Boorjian, Alireza Ghoreifi, Sia Daneshmand, Hooman Djaladat, John P. Sfakianos, Andrea Mari, Zine-Eddine Khene, David D'Andrea, Nozomi Hayakawa, Alberto Breda, Matteo Fontana, Kazutoshi Fujita, Alessandro Antonelli, Thomas van Doeveren, Christina Steinbach, Keiichiro Mori, Ekaterina Laukhtina, Morgan Roupret, Vitaly Margulis, Pierre Karakiewicz, Motoo Araki, Eva Comperat, Yasutomo Nasu, Shahrokh F. Shariat
Summary: The technical limitations of ureteroscopic biopsy are believed to contribute to the high upgrading rate in upper tract urothelial carcinoma (UTUC). However, the impact of tumor specific factors on upgrading has not been investigated. This study found that high-grade and low-grade biopsy results on ureteroscopy are associated with different biological and clinical features of UTUC tumors.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Taigo Kato, Satoru Yumiba, Wataru Nakata, Kosuke Nakano, Akira Nagahara, Kyosuke Matsuzaki, Yujiro Hayashi, Koji Hatano, Atsunari Kawashima, Tetsuya Takao, Kensaku Nishimura, Yasutomo Nakai, Masashi Nakayama, Kazuo Nishimura, Shingo Takada, Masao Tsujihata, Motohide Uemura, Norio Nonomura, Ryoichi Imamura
Summary: This study retrospectively investigated the efficacy and safety of nivolumab and axitinib as secondary treatment for patients with metastatic renal cell carcinoma (mRCC), and found that both drugs showed similar clinical benefits. Therefore, nivolumab and axitinib can be considered as options for sequential therapy following treatment with tyrosine kinase inhibitors (TKIs).
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Oncology
Yohei Inoguchi, Koji Hatano, Taigo Kato, Atsunari Kawashima, Toyofumi Abe, Shinichiro Fukuhara, Motohide Uemura, Hiroshi Kiuchi, Ryoichi Imamura, Norio Nonomura
Summary: This report describes a case of successful surgical and subsequent chemotherapy treatment for vascular leiomyosarcoma of the inferior vena cava. The rare tumor requires surgical intervention to prevent tumor-related symptoms. The surgical plan was determined in joint consultation and resulted in safe tumor resection and closure of the inferior vena cava.
INTERNATIONAL CANCER CONFERENCE JOURNAL
(2023)
Article
Oncology
Takero Hirata, Osamu Suzuki, Keisuke Otani, Akimitsu Miyake, Keisuke Tamari, Yuji Seo, Fumiaki Isohashi, Naoki Kai, Koji Hatano, Kazutoshi Fujita, Motohide Uemura, Ryoichi Imamura, Setsuo Tamenaga, Yutaro Yoshino, Yasutoshi Fumimoto, Yasuo Yoshioka, Norio Nonomura, Kazuhiko Ogawa
Summary: This study evaluated the toxicity and efficacy of different SBRT doses for PCa and selected an optimal dose. The results showed that an SBRT dose of 35 Gy per 5 fractions is less likely to cause adverse events than 37.5 and 40 Gy doses in PCa patients.
Article
Pathology
Satoshi Nojima, Tokimu Kadoi, Ayana Suzuki, Chiharu Kato, Shoichi Ishida, Kansuke Kido, Kazutoshi Fujita, Yasushi Okuno, Mitsuyoshi Hirokawa, Kei Terayama, Eiichi Morii
Summary: Deep learning systems have been developed to differentiate between follicular thyroid carcinoma and follicular adenoma based on histopathological assessment. The results show that the systems can predict the risk of recurrence, vascular invasion, and wide capsular invasion with a certain level of accuracy based on random views of tumor tissue histology.
Article
Urology & Nephrology
Takafumi Minami, Kazutoshi Fujita, Mamoru Hashimoto, Mitsuhisa Nishimoto, Shogo Adomi, Eri Banno, Masahiro Nozawa, Kazuhiro Nose, Kazuhiro Yoshimura, Masahiro Inada, Masaki Yokokawa, Kiyoshi Nakamatsu, Hirotsugu Uemura
Summary: Patients with prostate cancer treated with brachytherapy may have an increased risk of developing bladder cancer, especially those who smoke heavily and receive external beam radiotherapy as part of their treatment.
WORLD JOURNAL OF UROLOGY
(2023)
Review
Andrology
Makoto Matsushita, Kazutoshi Fujita, Koji Hatano, Marco A. De Velasco, Akira Tsujimura, Hirotsugu Uemura, Norio Nonomura
Summary: The gut microbiota, influenced by both environmental and genetic factors, has been found to have a significant impact on human health. Research has shown a close association between the gut microbiome and various non-intestinal diseases, particularly in the field of cancer biology and therapy. Prostate cancer cells are directly affected by the microbiota in local tissues and urine, suggesting a relationship between prostate cancer cells and the gut microbiota. The bacterial composition of the gut microbiota differs depending on prostate cancer characteristics, such as histological grade and castration resistance. Additionally, certain intestinal bacteria have been shown to be involved in testosterone metabolism, indicating a potential influence on prostate cancer progression and treatment. Basic research suggests that the gut microbiome plays a crucial role in prostate cancer biology through microbial-derived metabolites and components. This review focuses on the emerging relationship between the gut microbiome and prostate cancer, referred to as the gut-prostate axis.
WORLD JOURNAL OF MENS HEALTH
(2023)
Article
Urology & Nephrology
Mamoru Hashimoto, Nobutaka Shimizu, Saizo Fujimoto, Ken Kuwahara, Mitsuhisa Nishimoto, Shogo Adomi, Eri Banno, Takafumi Minami, Kazutoshi Fujita, Kazuhiro Yoshimura, Akihide Hirayama, Hirotsugu Uemura
Summary: This study aimed to elucidate the pathophysiology of post-micturition dribble (PMD) by analyzing pressure flow study (PFS) findings and symptoms questionnaire. The results showed that PMD was significantly associated with larger prostate volume (PV) and higher bladder outlet obstruction index (BOOI) evaluated by PFS. Furthermore, PMD was found to significantly exacerbate the quality of life (QOL). The severity of PMD and other m-IPSS sub-scores (except nocturia) could have intercorrelation with each other.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Naoki Matsumura, Kazutoshi Fujita, Mitsuhisa Nishimoto, Takafumi Minami, Hideo Tahara, Kazuhiro Yoshimura, Hirotsugu Uemura
Summary: The therapeutic landscape for metastatic hormone-sensitive prostate cancer has changed dramatically, with upfront systemic therapy showing improved survival and quality of life. Future research directions include triplet therapy, local therapy, and personalized treatment.
WORLD JOURNAL OF UROLOGY
(2023)